Neogen Corporation Revenue per Employee (NEOG), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Neogen Corporation  (NASDAQ: NEOG)
 

Neogen's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Neogen's Revenue per employee fell on a trailing twelve month basis to $ 330,618, but the productivity of Neogen's employees remained above the company average.
Within the Healthcare sector Employees of 2 other companies have achieved higher revenue per employee. While Neogen's total ranking has deteriorated compared to the previous quarter from 36 to 57. Neogen has 2,636 employees.


What is Sales per Employee Ratio?







NEOG Revenue per Employee (Feb 28 2026)
III. Quarter
(Nov 30 2025)
II. Quarter
(Aug 31 2025)
I. Quarter
(May 31 2025)
IV. Quarter
(Feb 28 2025)
III. Quarter
Y / Y Revenue Change -4.21 % -2.45 % -3.67 % -4.2 % -3.34 %
Sales per Employee (TTM) $ 330,618 334,133 336,275 339,293 343,063
NEOG's Total Ranking # 57 # 36 # 23 # 225 # 29
Seq. Revenue Change -6.09 % 7.52 % -7.88 % 2.99 % -4.37 %


Revenue per Employee Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 1
Healthcare Sector # 3
Overall Market # 57

Revenue per Employee Statistics
High Average Low
$ 320,598 $ 170,270 $ 77,206
(May 31 2024)   (Dec. 30, 2013)



Financial Statements
Neogen's Revenue MRQ $ 211 Millions Visit NEOG's Income Statement
Neogen's Revenues TTM $ 872 Millions Visit NEOG's aggregate revenue growth
What are NEOG's Sales? Visit NEOG's Sales by Segment


  News about Neogen Corporation Revenue per employee

Investor Alert Pomerantz Law Firm Investigates Potential Claims Against Neogen Corporation Amid Concerns of M...

New York, September 6, 2025 In a significant development for shareholders of Neogen Corporation (NASDAQ: NEOG), the Pomerantz Law Firm has announced that it is investigating potential claims on behalf of investors who may have suffered losses in their investment in the Company. This news comes as Neogen has been under scrutiny, prompting legal experts to assess whether the company’s actions may have led to breaches of fiduciary duty or other violations of investor rights.Neogen Corporation, a prominent player in food safety and animal health industries, has traditionally been recognized for its innovative products and services that help ensure the safety of food and animal products. However, recent events have raised concerns regarding its operational practices and financial reporting standards. The Pomerantz Law Firm’s proactive investigation is a response to these emerging uncertainties and seeks to assist investors seeking recourse for any potential damages incurred.




Other Ratios
Neogen's Income per Employee
Employees in In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NEOG's Revenue per Employee versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NEOG's Competitors
Revenue per Employee for NEOG's Suppliers
Revenue per Employee for NEOG's Customers

You may also want to know
NEOG's Sales Growth Rates NEOG's Pe Price to earnings ratio NEOG's Receivables Turnover Ratio NEOG's Stock Quote
NEOG's Net Income Growth Rates NEOG's Ps Price to Sales ratio NEOG's Sales per Employee NEOG's Asset Turnover Ratio
NEOG's Net Margin NEOG's Pb Price to Book ratio NEOG's Financial Strength Ratios NEOG's Dividend Payout Ratio
Date modified: 2026-09-08T15:11:40+00:00




Companies with similar Revenue per Employee for 12 months ending Feb 28 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Feb 28 2026Number of Employees Feb 28 2026
Enanta Pharmaceuticals Inc  576,775.00 $ 69.213  Million 120 
Elutia Inc   576,307.69 $ 14.984  Million 26 
Phibro Animal Health Corporation  575,862.96 $ 1,500.123  Million 2,605 
Delcath Systems Inc   571,032.05 $ 89.081  Million 156 
Embecta Corp   563,837.84 $ 1,043.100  Million 1,850 
Protagonist Therapeutics inc   561,083.33 $ 74.063  Million 132 
Milestone Scientific Inc   555,812.67 $ 8.337  Million 15 
Septerna Inc   555,807.69 $ 72.255  Million 130 
Phathom Pharmaceuticals Inc   552,269.54 $ 204.892  Million 371 
Iridex Corp  550,107.53 $ 51.160  Million 93 
Si bone inc   548,212.77 $ 206.128  Million 376 
Nexgel Inc   546,421.05 $ 10.382  Million 19 
Keros Therapeutics Inc   544,230.77 $ 42.450  Million 78 
10x Genomics Inc   541,268.25 $ 637.614  Million 1,178 
Nephros Inc   540,666.67 $ 19.464  Million 36 
Neuroone Medical Technologies Corp  540,044.17 $ 9.721  Million 18 
Caredx Inc   539,633.99 $ 412.820  Million 765 
Insulet Corporation  537,185.19 $ 2,900.800  Million 5,400 
Macrogenics Inc   536,119.45 $ 157.083  Million 293 
Henry Schein Inc   535,360.00 $ 13,384.000  Million 25,000 
Accuray Incorporated  528,915.95 $ 427.893  Million 809 
Instil Bio Inc   527,529.41 $ 8.968  Million 17 
Rhythm Pharmaceuticals Inc   524,553.14 $ 217.165  Million 414 
Iradimed Corporation  519,773.27 $ 86.282  Million 166 
Bausch Health Companies Inc   518,768.47 $ 10,531.000  Million 20,300 
Globus Medical Inc   516,777.33 $ 3,100.664  Million 6,000 
Perrigo Company Plc  515,740.74 $ 4,177.500  Million 8,100 
Cytomx Therapeutics Inc   515,101.45 $ 35.542  Million 69 
Orthofix Medical Inc   513,983.80 $ 824.944  Million 1,605 
Zimmer Biomet Holdings Inc   494,652.94 $ 8,409.100  Million 17,000 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.